-
Prolia compared with Alendronate in Women With Osteoporosis Polia
Comparative Persistence With Prolia and Weekly Alendronate in 6 Asia-Pacific countries: a Prospective Observational Study
You are eligible if you:
- are a Post Menopausal Female with Osteoporosis
- take Prolia (Denosumab) or Alendronate (Fosamax)
More information and Consent Form (PDF, 232KB)
Diabetes treatment for heart disease GPGN
The Effect of Tirzepatide versus Dulaglutide on Major Adverse Cardiovascular Events in Patients with Type 2 Diabetes (SURPASS-CVOT)
You are eligible if you:
• are at least 40 years of age
• have been diagnosed with type 2 diabetes
• have an established cardiovascular disease (coronary artery disease, cerebrovascular disease, or peripheral arterial disease).
Survey for Osteoporosis Fractures AM8810
Estimating Short-Term Indirect Cost and Physical Functioning Burden Associated with Osteoporotic Fractures
You may be eligible if you:
- are a woman aged ≥50 years
Type II Diabetic Patients with Kidney Disease AZ study
A Phase 2b, Multicentre, Randomised, Double-blind, Placebo-controlled, and Open-label Comparator Study of Cotadutide in Participants Who Have Chronic Kidney Disease with Type 2 Diabetes Mellitus
You may be eligible if you:
- have Type 2 diabetes and problems with your kidney function
- are aged between 18 – 79 years old
- are taking Insulin or any oral combination therapy including Metformin
The Metformin Aneurysm Trial (MAT)
An investigator initiated and conducted, multicentre, international, double-blinded, placebo-controlled, parallel-group, randomised controlled trial to determine the effect of metformin on abdominal aortic aneurysm (AAA) associated events, including AAA repair and AAA mortality (due to aneurysm rupture).
You may be eligible if you:
- have an abdominal aortic aneurysm
- are aged between 18 – 79 years old
- are not taking metformin
Weight Loss Medication
A Phase II, randomized, double blind, parallel group,46 weeks dose-finding study of BI 456906 administered once weekly subcutaneously compared with placebo in patients with obesity or overweight
You are eligible if you:
- are aged between 18 - 75 years, inclusive
- are obese or overweight (BMI equal to or above 27kg/m2)
- have not had a dramatic change in weight over the last 12 weeks
- do not have Type I or Type II diabetes
Potential New Treatment for People with Chronic Kidney Disease
Randomised, double-blind, placebo-controlled and parallel dose group trial to investigate efficacy
and safety of multiple doses of oral BI 690517 over 14 weeks, alone and in combination with
empagliflozin, in patients with diabetic and non-diabetic chronic kidney disease.
You may be eligible if you:- are 18 years of age or older
- have diabetic or non-diabetic Chronic kidney disease
- are currently receiving medication for your condition
A new Novavax vaccine for the treatment of the Omicron COVID variant.
A Phase 3, Randomized, Observer Blinded Study to Evaluate the Safety and Immunogenicity of Two Booster Doses of the NVX-CoV2515 and Bivalent SARS-CoV-2 rS Vaccines in Adults Previously Vaccinated with Other COVID-19 Vaccines.
You may be eligible if you:
- are aged 18 to 64 years of age
- have previously received 2 or 3 doses of either the Moderna and/or Pfizer/BioNTech vaccines
- are in good general health, as determined by medical history, physical exam, and vital signs
- have no current autoimmune or immunodeficiency disease/condition
- have not had previous allergic reactions to vaccines
Vaccine for Respiratory Synctial Virus (RSV)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of Respiratory Syncytial Virus Prefusion F Subunit Vaccine When Coadministered With Seasonal Inactivated Influenza Vaccine in Adults ≥65 Years of Age
Respiratory syncytial virus is a common virus that causes lower respiratory infections. Most people recover quickly from these infections, but infants and young children, older adults, and people with a weakened immune system may be at greater risk for more severe infections.
You may be eligible if you:
- are aged 65 or over
- generally healthy or have stable chronic health conditions
- have not already received an RSV vaccine at any time,
- have not received the flu vaccine in the past 6 months
- Home
- About us
- Publications
- Organisational Structure
- Consumer and Community Engagement
- Eastern Health Foundation
- Volunteers
- Policies and Guidelines
- Access to Patient Records
- Services
- COVID-19 Community Pathways
- COVID-19 Screening Clinics
- COVID-19 Vaccination Clinics
- A–Z Service Directory
- Aboriginal Health
- Acute Specialist Clinics (Outpatients)
- Patient Revenue Services
- Telehealth
- Emergency Department
- Eastern Centre Against Sexual Assault
- Allied Health Services
- Maternity Services
- Mental Health and Wellbeing Service
- Our Response to the Royal Commission into Victoria’s Mental Health System
- Mental Health Wellbeing and Recovery
- Lived Experience Workforce - LEW
- Families where a Parent has a Mental Illness (FaPMI)
- Aboriginal and Torres Strait Islander Social and Emotional Wellbeing
- Child Youth Mental Health and Wellbeing Service
- Adult Mental Health
- Dual Diagnosis
- Older Adult Mental Health and Wellbeing Service
- NDIS
- Consultation-Liaison (CL) Psychiatry
- Eastern Mental Health Service Coordination Alliance
- Spectrum
- Language Services
- Imaging Services
- Pathology
- Alcohol and Drug Treatment (Turning Point)
- Locations
- Research & Ethics
- Latest News
- Guidance
- Research Programs
- Education and Training
- Research Data Services
- Library Services
- Funding Opportunities
- Research Enquiries
- Health Professionals
- Latest News
- Careers
- Contact us
Get Connected